Biomarker discovery using miRNA expression array in patients with ovarian cancer treated with dose-dense Paclitaxel combined with intraperitoneal chemotherapy of Carboplatin

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592527
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Saitama Medical University
• Principal Investigator: HASEGAWA Kosei 埼玉医科大学, 医学部, 准教授 (30534193)
• Co-Investigator(Kenkyū-buntansha): EGUCHI Hidetaka 埼玉医科大学, 医学部, 准教授 (00260232) ; WADA Satoshi 埼玉医科大学, 医学部, 助教 (80438837)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 卵巣癌 / マイクロRNA / 遺伝子発現 / バイオマーカー

Outline of Final Research Achievements

We investigated the biomarker of ovarian cancer using the samples and clinical information of a phase II study of dose-dense Paclitaxel combined with intraperitoneal chemotherapy of Carboplatin (ddTCip). We performed miRNA array, and analyzed miRNA expression and its relationship with clinical information. We found decreased levels of miR-100, miR-126, and miR-145 expression in patients with PR or CR, which suggests potential predictive marker for ddTCip therapy. In addition, we observed increased levels of miR-142-3p and miR-28-5p expression in platinum resistant ovarian cancer patients. Confirmation and validation is warranted in on-foing phase III trial of ddTCip therapy (iPocc trial).

Free Research Field

婦人科腫瘍学